Arno Therapeutics appoints new CEO
This article was originally published in Scrip
Executive Summary
Arno Therapeutics, a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, has appointed Glenn Mattes president, chief executive officer and member of the board of directors. He has served as president of Tibotec Therapeutics, a Johnson & Johnson operating company focused on oncology and virology therapeutics, since 2002.